Is CYTX a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,209 people get CYTX articles and Market Currents by email alert.

Get email alerts on CYTX »

HEADLINES:

Energy And Biotechs With Recent Earnings Catalysts
David Zanoni • Mon, May 13 • 3 Comments
Position Yourself For Big Returns In The Stem Cell Space: Jason Kolbert
Life Sciences Report • Mon, May 13 • 3 Comments
Cytori Therapeutics Management Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 9
Cytori Reports First Quarter 2013 Business and Financial Results

Business Wire (May 9, 2013)
Cytori to Webcast First Quarter Financial Results on May 9

Business Wire (May 2, 2013)
Cleveland BioLabs Offers Medical Countermeasures Against Potential Terrorist Attacks
Scott Matusow • Tue, Apr 23 • 5 Comments
Investing In The Stem Cell Sector: An Overview
EnhydrisPECorp • Wed, Apr 17 • 25 Comments
North Korean Threats And The Cytori - BARDA Stem Cell Collaboration
Wall Street Titan • Tue, Apr 16 • 2 Comments
Companies That Can Mend The Biotech Market: Stephen Brozak
Life Sciences Report • Fri, Apr 12 • 7 Comments
Cytori to Present at Regen Med Investor Day 2013 on April 17

Business Wire (Apr 10, 2013)
Cytori to Webcast at the Future Leaders in the Biotech Industry Conference on April 5, 2013

Business Wire (Mar 29, 2013)
Cytori Patents Method of Treating Renal Diseases Using Adipose-Derived Regenerative Cells

Business Wire (Mar 28, 2013)
Cytori Provides Update in 510(k) Appeal Decision

Business Wire (Mar 22, 2013)
The Stem Cell Revolution Can Jump Start Your Portfolio: Jason Kolbert
Life Sciences Report • Fri, Mar 15 • 16 Comments
Cytori Therapeutics To Present at the 25th Annual Roth Conference on March 18

Business Wire (Mar 11, 2013)
Cytori Therapeutics Management Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Mar 7 • 1 Comment
Cytori Reports 2012 Business and Financial Results; Provides Outlook for 2013

Business Wire (Mar 7, 2013)
Cytori to Webcast Fourth Quarter and Year End Financial Results on March 7

Business Wire (Feb 28, 2013)
Cytori Appoints Dr. Steven Kesten as Executive Vice President and Chief Medical Officer

Business Wire (Feb 26, 2013)
Cytori's EU Approval For Intravase - Intentionally Downplayed?
Wall Street Titan • Mon, Feb 25 • 6 Comments

To learn more about Seeking Alpha Pro, click here.

North Korean Threats And The Cytori - BARDA Stem Cell Collaboration
Wall Street Titan • Tue, Apr 16 • 2 Comments
Cytori's EU Approval For Intravase - Intentionally Downplayed?
Wall Street Titan • Mon, Feb 25 • 6 Comments
Worth The Wait: Implications Of Cytori Therapeutics' $106 Million BARDA Contract
Wall Street Titan • Mon, Oct 8, 2012 • 16 Comments
With Cytori Therapeutics, The Waiting Is The Hardest Part
Wall Street Titan • Tue, Aug 14, 2012 • 5 Comments
New Okyanos Heart Institute Makes Big Bet On Cytori Therapeutics Technology
Wall Street Titan • Tue, Apr 10, 2012 • 7 Comments
Cytori Is A Compelling Short Sale Opportunity
Martin Shkreli • Mon, Mar 19, 2012 • 17 Comments
European Scandal Could Help Cytori Therapeutics
Wall Street Titan • Wed, Jan 11, 2012 • 11 Comments
Good Sign For Cytori Therapeutics: Athletes Seek Out Stem Cell Therapy
Wall Street Titan • Wed, Oct 12, 2011 • 8 Comments
Cytori Therapeutics Q2/11 Results Are a Net Loss
Henry McCusker • Wed, Aug 10, 2011 • 1 Comment
Cytori Therapeutics Completes Equity Agreement
Henry McCusker • Tue, Jul 12, 2011
Cytori Therapeutics and Its Publicly-Traded Outstanding Warrants: A Lesson on Leverage
Wall Street Titan • Thu, Jun 16, 2011 • 5 Comments
Cytori Therapeutics: Sales Miss? Yes. Bad Quarter? No
Wall Street Titan • Fri, May 6, 2011 • 5 Comments
Cytori Therapeutics Management - Putting Its Money Where Its Mouth Is
Wall Street Titan • Wed, Apr 27, 2011 • 3 Comments
Cytori: A Must Own Biotech
Jason Napodano • Wed, Apr 13, 2011 • 8 Comments
Growing Regenerative Medicine Market Provides Opportunities for Cytori Therapeutics
Douglas Cress • Tue, Aug 24, 2010 • 1 Comment
Joe Feshbach's Highest Conviction Position: A Regenerative Medicine 'Game Changer'
Joe Feshbach • Tue, Jan 12, 2010 • 27 Comments
Cytori Gets FDA 510(k) Celution Clearance, Heart Data Pending
Mike Havrilla • Sun, Jan 10, 2010 • 3 Comments
Cytori Therapeutics: Don't Buy In to the Momentum
Jay Springate • Thu, Dec 17, 2009 • 15 Comments
Cytori Therapeutics: Natural Celution for Breast Reconstruction
Mike Havrilla • Sun, Dec 13, 2009
Cytori Therapeutics' Cardiac Celution: Encouraging Interim Data
Mike Havrilla • Wed, Sep 23, 2009 • 1 Comment

Energy And Biotechs With Recent Earnings Catalysts
David Zanoni • Mon, May 13 • 3 Comments
Position Yourself For Big Returns In The Stem Cell Space: Jason Kolbert
Life Sciences Report • Mon, May 13 • 3 Comments
Cleveland BioLabs Offers Medical Countermeasures Against Potential Terrorist Attacks
Scott Matusow • Tue, Apr 23 • 5 Comments
Investing In The Stem Cell Sector: An Overview
EnhydrisPECorp • Wed, Apr 17 • 25 Comments
Companies That Can Mend The Biotech Market: Stephen Brozak
Life Sciences Report • Fri, Apr 12 • 7 Comments
The Stem Cell Revolution Can Jump Start Your Portfolio: Jason Kolbert
Life Sciences Report • Fri, Mar 15 • 16 Comments
Profit Growth On The Horizon For Investors Of 3 Companies Advancing Regenerative Medicine
Amy Baldwin • Mon, Jan 28 • 6 Comments
Stephen Brozak: Changing The Way Money Is Made And Diseases Are Cured
Life Sciences Report • Fri, Jan 25 • 3 Comments
3 Stocks With Recent Intensive Insider Buying
Markus Aarnio • Wed, Dec 26, 2012 • 79 Comments
2 Small-Cap Healthcare Companies Investors Should Consider Based On Recent Developments
Matt Schilling • Thu, Oct 11, 2012 • 4 Comments
6 Cash-Heavy Biotech Stocks With Analyst Endorsements
ZetaKap • Thu, Aug 23, 2012
8 Biotechnology Stocks With Good Liquidity That Analysts Rate As Buy
ZetaKap • Fri, May 25, 2012
Record 1Q Sales: Nerve Regeneration Products Gaining Traction
Cockrell Group • Wed, May 16, 2012
Stem Cell Biotechs Report 2011 Year In Review: Part II
Chemistfrog • Mon, May 7, 2012 • 1 Comment
BioTime Is Running Out Of Time - Short-Sell Idea
Martin Shkreli • Wed, Apr 11, 2012 • 20 Comments
7 Stocks In The Healthcare Space Reversing Their Short-Term Bearish Trends
Kinetic Investments • Tue, Feb 21, 2012 • 2 Comments
12 Highly Shorted Biotech Stocks Being Snapped Up By Insiders
Kapitall • Wed, Feb 15, 2012 • 1 Comment
Monday's Noteworthy Insider Buys And Sells In Healthcare, Energy And Services Sectors
GuruFundPicks • Tue, Feb 7, 2012
7 Low-Priced Stocks With Fresh Insider Buying
Rougemont • Mon, Dec 19, 2011 • 1 Comment
Analyzing Wednesday's Noteworthy Insider Buys And Sells
GuruFundPicks • Thu, Dec 15, 2011

Cytori Therapeutics Management Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 9
Cytori Therapeutics Management Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Mar 7 • 1 Comment
Cytori Therapeutics Management Discusses Q3 2012 Results - Earnings Call Transcript
Thu, Nov 8, 2012
Cytori Therapeutics Management Discusses Q2 2012 Results - Earnings Call Transcript
Thu, Aug 9, 2012
Cytori Therapeutics Q3 2009 Earnings Call Transcript
Mon, Nov 9, 2009
Cytori Therapeutics, Inc. Q4 2008 Earnings Call Transcript
Sat, Mar 21, 2009
Cytori Therapeutics, Third Quarter Year Earnings Call Transcript
Mon, Nov 10, 2008
Cytori Therapeutics Q4 2007 Earnings Call Transcript
Wed, Mar 12, 2008

Cytori Reports First Quarter 2013 Business and Financial Results

Business Wire (May 9, 2013)
Cytori to Webcast First Quarter Financial Results on May 9

Business Wire (May 2, 2013)
Cytori to Present at Regen Med Investor Day 2013 on April 17

Business Wire (Apr 10, 2013)
Cytori to Webcast at the Future Leaders in the Biotech Industry Conference on April 5, 2013

Business Wire (Mar 29, 2013)
Cytori Patents Method of Treating Renal Diseases Using Adipose-Derived Regenerative Cells

Business Wire (Mar 28, 2013)
Cytori Provides Update in 510(k) Appeal Decision

Business Wire (Mar 22, 2013)
Cytori Therapeutics To Present at the 25th Annual Roth Conference on March 18

Business Wire (Mar 11, 2013)
Cytori Reports 2012 Business and Financial Results; Provides Outlook for 2013

Business Wire (Mar 7, 2013)
Cytori to Webcast Fourth Quarter and Year End Financial Results on March 7

Business Wire (Feb 28, 2013)
Cytori Appoints Dr. Steven Kesten as Executive Vice President and Chief Medical Officer

Business Wire (Feb 26, 2013)
Intravase® Approval Opens Vascular Market for Cytori

Business Wire (Feb 25, 2013)
Cytori Announces Presentation at Biotech Showcase™ on January 8th

Business Wire (Jan 4, 2013)
Cytori Therapeutics Prices $20.0 Million Public Offering of Common Stock

Business Wire (Dec 14, 2012)
Cytori Therapeutics Proposes Public Offering of Common Stock

Business Wire (Dec 13, 2012)
Cryptoglandular Fistula Repair Case Series Using Cytori Cell Therapy Published in the British Medical Journal: Case Reports

Business Wire (Nov 12, 2012)
Cytori Provides Business Update and Reports Third Quarter and Nine Month 2012 Results

Business Wire (Nov 8, 2012)
Cytori to Webcast Third Quarter Financial Results on November 8

Business Wire (Nov 1, 2012)
Cytori Therapeutics Announces Company Presentation the 2012 Stem Cell Meeting on the Mesa’s Investor and Partnering Forum on October 30

Business Wire (Oct 26, 2012)
Cardiovascular and Chronic Liver Disease Cell Therapy Clinical Studies Approved in Japan

Business Wire (Oct 25, 2012)
Investigator-Sponsored Cell Therapy Clinical Study for Scleroderma Initiated in France

Business Wire (Oct 23, 2012)

CYTX vs. ETF Alternatives

Company Description

Cytori Therapeutics, Inc., develops, manufactures, and sells medical products to enable the practice of regenerative medicine. Regenerative medicine describes the emerging field that aims to repair or restore lost or damaged tissue and cell function. Our commercial activities are currently... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 9, 6:00 PM Cytori Therapeutics (CYTX): Q1 EPS of -$0.11 beats by $0.04. Revenue of $3.8M beats by $0.57M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Friday, March 22, 3:37 PM Cytori Therapeutics (CYTX -2.2%) retreats in afternoon trading after a U.S. Appeals court upheld an FDA decision not to approve two stem-cell therapy devices. The court agreed with the FDA, noting that the devices weren't "substantially equivalent to the cited predicate devices." CYTX says it plans to continue to seek approval for the therapy through the Premarket Approval route, which is far more complex and time-consuming than the traditional 510(k) premarket process. Comment! [Healthcare, On the Move]
Thursday, March 7, 5:07 PM Cytori (CYTX): Q4 EPS of -$0.06 beats by $0.10. Revenue of $4.3M beats by $0.2M. (PR) 2 Comments [Earnings, Breaking News, Healthcare]
Wednesday, March 6, 9:10 AM Premarket gainers: PRAN +13%. PBR +12%. CYTX +9%. PPHM +8%. GEVO +8%. MTG +8%. TSL +8%. HNR +7%. BIG +7%.PBR.A +6%. PAY +5%. WPRT +5%.
Losers: AVAV -25%. TFM -11%. AEO -9%. SOHU -8%. QIHU -5%. NBG -5%. Comment! [On the Move]
Wednesday, March 6, 8:26 AM Roth Capital initiates Cytori Therapeutics (CYTX) at a Buy and gives it a price target of $8, well above the company's close of $2.69 yesterday. Roth's move comes after Cytori said last week that it has received the CE Mark in Europe for it reagent Intravase, which is used in the treatment of heart-failure patients. Comment! [Healthcare, Quick Ideas]
Monday, February 25, 3:02 PM Cytori Therapeutics (CYTX +2%) gains today after saying it's received a CE Mark in Europe for Intravase, a reagent intended to be used with CYTX's Celution System for preparing stem and regenerative cells for intravascular delivery into the same patient. Comment! [Healthcare, On the Move]
Friday, December 14, 2012, 12:45 PM Midday top 10 gainers: ALIM +30%. STXS +19%. QUAD +18%. RIGL +15%. CHOP +19%. OTT +16%. ZAZA +13%. ALU +12%. AXR +11%. SZYM +11%.
Midday top 10 Losers: YOD -23%. LPTN -18%. CYTX -15%. ZQK -15%. BBY -15%. USNA -11%. PAY -10%. MEIP -9%. LAS -9%. VGZ -10%. Comment!
Friday, December 14, 2012, 10:40 AM Cytori Therapeutics (CYTX -14.9%) takes a hit this morning after pricing its 7M share offering at $2.85, a 14% discount to Thursday's close. Net proceeds are expected to be around $18.5M. The company will likely use the proceeds for the ongoing development, manufacture, marketing and sale of its Celution System. CYTX announced the offering late yesterday, at the time saying it would offer an undisclosed number of shares, subject to market conditions. Comment! [Healthcare, On the Move]
Friday, December 14, 2012, 9:10 AM Premarket gainers: ALXA +18%. ALU +10%. TIVO +5%. ADBE +5%.
Losers: CYTX -15.66%. CNC -8%. BBY -8%. PAY -7%. ISIS -6%. FBR -5%. Comment! [On the Move]
Thursday, December 13, 2012, 5:37 PM After-hours top gainers, as of 5:15 p.m.: ADBE +5%. SCVL +2%. GWAY +2%. ONNN +2%. AVGO +2%.
After-hours top losers: ZQK -14%. CYTX -13%. VGZ -9%. PAY -6%. TSON -6%. Comment! [On the Move]
Thursday, December 13, 2012, 4:42 PM Cytori Therapeutics (CYTX) proposes a common stock offering. The size and terms of the offering were not disclosed. Lazard Capital Markets LLC is acting as the sole book-running manager of the offering. Comment! [Healthcare]
Friday, November 9, 2012, 12:45 PM Midday top 10 gainers: HWG +66%. KIPS +41%. KYAK +27%. ZIP +25%. SQNM +22%. UBNT +19%. DGIT +17%. SQI +16%. CYTX +16%. ISIS +15%. Midday top 10 Losers: GRPN -27%. DTSI -26%. SCLN -24%. IDN -23%. RNDY -21%. III -17%. ADEP -17%. OSG -17%. STRA -16%. PTIX -15%. Comment!
Tuesday, October 23, 2012, 12:34 PM Cytori Therapeutics (CYTX -0.7%) says that an investigator-sponsored and funded clinical study evaluating it's cell therapy as a potential treatment for scleroderma has been approved to begin in France by the National Agency for the Safety of Medicines and Health Products. Comment! [Healthcare, Global & FX]
Thursday, October 11, 2012, 12:04 PM Cytori Therapeutics (CYTX +6%) moves up after announcing its begun its Athena clinical trial to investigate it's cell therapy in patients who suffer from a severe form of untreatable heart failure due to chronic myocardial ischemia. The first patient was treated at the Minneapolis Heart Institute Foundation in September and has already undergone a seven day follow-up assessment. Comment! [Healthcare, On the Move]
Monday, October 1, 2012, 12:45 PM Midday top 10 gainers: CRDN +43%. FONR +34%. BIOF +19%. VSR +17%. MTG +16%. SNTA +16%. VSNT +15%. PATK +14%. MGI +12%. SFUN +12%.
Top 10 Losers: NC -65%. TYC -49%. GMAN -24%. BYFC -17%. THLD -17%. PPHM -16%. GNI -11%. OCZ -10%. ROSG -10%. CYTX -8%. 1 Comment [On the Move]
Friday, September 28, 2012, 1:45 PM Maxim weighs in on Cytori Therapeutics' (CYTX +18%) new government contract, calling it a significant strategic positive. The firm reiterates its Buy rating on the stock with a $10 price target. 1 Comment [Healthcare, On the Move]

FredChen23
Is Calhoun going to make good on the promise from Q3 CC? Hope the deal he meant would go through wasn't the one with Lazard...smh $CYTX
12/20/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

skywola
I'm going long on CYTX, CUR and a few others . . . Stem cell related companies have a bright future.
10/1/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Bryant
CEO of Cytori Therapeutics (CYTX) was on Bloomberg TV about the future of their technology: stem cells from fat cells. Sounds interesting.
9/28/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ron49er
CYTX with $10 target http://bit.ly/TMsOM3
9/28/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
6 Cash-Heavy Biotech Stocks With Analyst Endorsements http://bit.ly/TXLKnB $CYTX $PLX $GTXI $HALO $ILMN $THRX @ZetaKap
8/23/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Clark
Short XIDE, ELY, CYTX http://seekingalpha.com/p/j05h
7/24/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
8 Biotechnology Stocks With Good Liquidity That Analysts Rate As Buy http://bit.ly/MxU9KJ $DYAX $CADX $BMRN $CYTX $CVM $AMGN $ALXN $CELG
5/25/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

bdubya13
in CYTX at 2.22
4/18/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Berenstain Bulls
Long CYTX & PSTI. Any favorites for stemcells / regenerative medicine? http://on.wsj.com/GDl02x
3/20/12
Reply (4)

• !Report Abuse
View all 4 replies
The Berenstain Bulls: Let's hope so for my broke a** sake, LOL
3/20/12
• !Report Abuse
bigfoot: I may have lost money on my STEM stock, but more than made up for it with my AFFY stock!
3/20/12
• !Report Abuse
Add a reply...

140 characters

Henry McCusker
Mid-Day Movers: BioTime (AMEX: BTX), Cytori (CYTX), Geron (GERN), Neuralstem (AMEX: CUR), ReNeuron (RENE.LON), ThermoGenesis (KOOL)
10/26/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

The Berenstain Bulls
Long CYTX & PSTI. Any favorites for stemcells / regenerative medicine? http://on.wsj.com/GDl02x
3/20/12
Reply (4)

• !Report Abuse
View all 4 replies
The Berenstain Bulls: Let's hope so for my broke a** sake, LOL
3/20/12
• !Report Abuse
bigfoot: I may have lost money on my STEM stock, but more than made up for it with my AFFY stock!
3/20/12
• !Report Abuse
Add a reply...

140 characters

CYTX Cytori Therapeutics Inc

CYTX

Cytori Therapeutics Inc